Resverlogix (RVX.TO) Stock Price
Resverlogix Price
Revenue at Resverlogix has contracted by 26.9% per year over the past 4 years to 82,875.89 USD. Earnings per share have declined at 74.6% per year over the last 8 years. Resverlogix's net margin stands at -26,691.8%, down from -5,707.1% several years earlier.
Resverlogix stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Resverlogix business model & stock analysis
Frequently asked questions about Resverlogix
The business model of Resverlogix Corp is focused on developing innovative therapies in the field of epigenetics to address unmet medical needs. The company specializes in the discovery and development of small molecules that target specific proteins involved in the regulation of gene expression. Resverlogix Corp aims to provide novel treatments for conditions such as cardiovascular diseases and other related disorders. By leveraging their expertise in epigenetics, the company strives to offer groundbreaking therapies that have the potential to significantly improve patients' lives.
Resverlogix Corp is primarily active in the pharmaceutical industry.
Some of the main competitors of Resverlogix Corp in the market include Novartis AG, Pfizer Inc., Amgen Inc., and AstraZeneca PLC.
Resverlogix Corp, founded in 2001, is a Canadian biotechnology company specializing in developing innovative therapies for cardiovascular diseases. The company focuses on addressing unmet medical needs, primarily targeting high-risk patients with chronic diseases. Resverlogix Corp is at the forefront of pioneering epigenetic drug discovery and development, specifically targeting BET bromodomain inhibition. Their leading compound, Apabetalone, has shown promising results in clinical trials, demonstrating its potential to reduce major adverse cardiovascular events. With a commitment to improving patient outcomes and advancing cardiovascular health, Resverlogix Corp has emerged as a prominent player in the biotech industry.
Resverlogix Corp has achieved several significant milestones in its journey. The company successfully completed Phase 3 clinical trials for its lead drug candidate, apabetalone, for the treatment of high-risk cardiovascular diseases. Moreover, Resverlogix Corp received a Special Protocol Assessment from the U.S. FDA for the Phase 3 BETonMACE trial, indicating the agency's support for the trial design. The company's achievements also include securing strategic partnerships and collaborations with renowned pharmaceutical companies, enhancing its research capabilities and market presence. These milestones demonstrate Resverlogix Corp's commitment to advancing innovative treatments for serious diseases and highlights its strong potential for growth and success in the pharmaceutical industry.
Resverlogix Corp is primarily present in Canada and the United States.
Resverlogix Corp represents values of innovation, excellence, and commitment to improving patients' lives. With a strong corporate philosophy focused on advancing groundbreaking medical treatments, Resverlogix Corp strives to redefine the standard of care in cardiovascular diseases. Through their leading-edge drug development platform, BETonMACE™, the company aims to deliver transformative therapies that target unmet medical needs. Resverlogix Corp is dedicated to scientific excellence, collaboration with global experts, and ensuring the highest ethical standards in their research and development endeavors. Through their unwavering dedication, Resverlogix Corp is committed to making a positive impact on the lives of patients worldwide.
5 analysts currently rate the Resverlogix stock: 4 recommend buying, 1 holding and 0 selling.
Converted at the current exchange rate, the Resverlogix share trades at 0.06 EUR (0.06 USD).
The Resverlogix share (RVX.TO) is listed on 6 stock exchanges, including: London (0VF9.L), Toronto (RVX.TO), Frankfurt (RFS.F), München (RFS.MU), Düsseldorf (RFS.DU).
Resverlogix Corp is a biopharmaceutical company focused on developing drugs that target lipid and lipoprotein metabolism. The company was founded in 2001 and is headquartered in Calgary, Canada. Resverlogix Corp specializes in the discovery and development of therapeutics for the treatment of serious diseases such as Alzheimer's, Parkinson's, cancer, and diabetes.
The revenue cannot currently be calculated for Resverlogix.
The profit cannot currently be calculated for Resverlogix.
The P/E ratio cannot be calculated for Resverlogix at the moment.
The P/S cannot be calculated for Resverlogix currently.
The Eulerpool Quality Score for Resverlogix is 2/10.
The ISIN of Resverlogix is CA76128M1086. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Resverlogix is A0DP7L. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Resverlogix is RVX.TO. The ticker symbol is used to trade Resverlogix shares on the stock exchange.
Resverlogix stock
Resverlogix Peer Group
Resverlogix Ticker
Resverlogix FIGI
All fundamentals and in-depth analysis of Resverlogix
Our stock analysis for Resverlogix stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Resverlogix. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.